URB-597
FAAH inhibitor / Potent and selective fatty acid amide hydrolase (FAAH) inhibitor, IC50 = 3-5 nM1. Produces cannabinoid CB1 and CB2 receptor-mediated analgesia in inflammatory pain states without causing side effects associated with cannabinoid receptor activation2. Attenuates the anxiolytic-like effect of acetaminophen in a mouse model3. Exerts anti-inflammatory effects in rat hippocampus and ameliorates age-related deficits4. Off target effects: Reduces tyrosine hydroxylase expression5.
Biochemicals & reagents
546141-08-6
1) Piomelli et al. (2006), Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597); CNS Drugs Rev., 12 21 2) Jayamanne et al. (2006), Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models; Br. J. Pharmacol., 147 281 3) Zaitone et al. (2012), Inhibition of fatty acid amide hydrolase by URB597 attenuates the anxiolytic-like effect of acetaminophen in the mouse elevated plus-maze test; Behav. Pharmacol., 23 417 4) Murphy et al. (2012), The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation; Neuroinflamation, 9 79 5) Bosier et al. (2013), The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB- and FAAH-independent mechanisms; Br. J. Pharmacol., 169 794
RT
TARGET: Serine hydrolase -- PATHWAY: Cannabinoid receptor; Fatty acid metabolism -- RESEARCH AREA: Neuroscience -- DISEASE AREA: Pain; Inflammation